logo-loader
viewHumanigen, Inc.

Humanigen updates on its clinical collaboration with Gilead Sciences subsidiary, Kite

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant spoke with Proactive at the 2019 BIO Investor Forum in San Francisco. 

Durrant updated investors on the opportunity within its clinical collaboration with Kite, a company belonging to Gilead Sciences Inc (NASDAQ:GILD), along with Humanigen's efforts to develop its own CAR-T cells, a new approach to cancer therapy involving altered T cells.

Quick facts: Humanigen, Inc.

Price: 0.36 USD

OTCMKTS:HGEN
Market: OTCQB
Market Cap: $40.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Humanigen inks licensing agreement with the University of Zurich to...

Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based company has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers. Durrant says Humanigen has received an exclusive licensing...

on 07/22/2019

2 min read